1184915-45-4 Usage
General Description
(2-bromo-3-fluorophenyl)methanol is a chemical compound with the molecular formula C7H6BrFO. It is a white to off-white crystalline powder with a molecular weight of 203.03 g/mol. (2-bromo-3-fluorophenyl)methanol is commonly used as an intermediate in the synthesis of various pharmaceutical and agrochemical products. It is also used in the production of organic compounds and as a reagent in chemical reactions. (2-bromo-3-fluorophenyl)methanol is known for its potential to act as a chiral building block in the synthesis of various biologically active molecules, making it an important compound in medicinal chemistry and drug development. However, it is important to handle this compound with caution as it may be harmful if ingested, inhaled, or comes into contact with skin.
Check Digit Verification of cas no
The CAS Registry Mumber 1184915-45-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,4,9,1 and 5 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1184915-45:
(9*1)+(8*1)+(7*8)+(6*4)+(5*9)+(4*1)+(3*5)+(2*4)+(1*5)=174
174 % 10 = 4
So 1184915-45-4 is a valid CAS Registry Number.
1184915-45-4Relevant articles and documents
Pyridopyrimidinone compound and application thereof
-
Paragraph 0264-0265, (2021/01/24)
The invention provides a pyridopyrimidinone compound with a structure as shown in a general formula (II) and application thereof. Researches prove that the compound provided by the invention can effectively inhibit KRAS G12C mutation. KRAS mutation accounts for a large proportion in tumors, no approved drug is obtained for treatment at present, and the compound provided by the invention has the potential to become a therapeutic drug for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) carrying KRAS G12C mutation, and has a great application value.
QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY
-
Paragraph 0240; 0241, (2016/02/29)
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
